MSA Clinical Features and Diagnosis

📖 Wiki Page

mechanism1024 wordssynced 2026-04-02

MSA Clinical Features and Diagnosis

Multiple System Atrophy (MSA) presents with a complex clinical phenotype that combines parkinsonism, cerebellar dysfunction, and autonomic failure in varying combinations. This page details the clinical presentation, diagnostic criteria, disease variants, and progression patterns that characterize this devastating disorder.

Clinical Phenotypes

MSA with Parkinsonian Features (MSA-P)

The Parkinsonian variant accounts for approximately 70% of MSA cases:

Core Motor Features:

Bradykinesia: Progressive slowing of voluntary movements
Rigidity: Cogwheel or lead-pipe rigidity, often symmetric
Postural instability: Frequent falls, typically within 3 years of onset
Resting tremor: Less prominent than in Parkinson's disease (10-20%)

Distinguishing from Parkinson's Disease:

Rapid progression (median time to falls: 4-5 years)
Poor levodopa response (<30% achieve sustained benefit)
Early autonomic failure (within 1-2 years of motor onset)
Symmetric onset (vs. asymmetric in PD)

MSA with Cerebellar Features (MSA-C)

The cerebellar variant accounts for approximately 30% of cases:

Core Cerebellar Features:

Gait ataxia: Wide-based, unsteady gait with frequent falls
Limb dysmetria: Impaired coordination in arm/leg movements
Scanning speech: Slow, irregular speech with inappropriate pauses
Nystagmus: Gaze-evoked horizontal nystagmus, often vertical

...

MSA Clinical Features and Diagnosis

Clinical Phenotypes

MSA with Parkinsonian Features (MSA-P)

The Parkinsonian variant accounts for approximately 70% of MSA cases:

Core Motor Features:

Bradykinesia: Progressive slowing of voluntary movements
Rigidity: Cogwheel or lead-pipe rigidity, often symmetric
Postural instability: Frequent falls, typically within 3 years of onset
Resting tremor: Less prominent than in Parkinson's disease (10-20%)

Distinguishing from Parkinson's Disease:

Rapid progression (median time to falls: 4-5 years)
Poor levodopa response (<30% achieve sustained benefit)
Early autonomic failure (within 1-2 years of motor onset)
Symmetric onset (vs. asymmetric in PD)

MSA with Cerebellar Features (MSA-C)

The cerebellar variant accounts for approximately 30% of cases:

Core Cerebellar Features:

Gait ataxia: Wide-based, unsteady gait with frequent falls
Limb dysmetria: Impaired coordination in arm/leg movements
Scanning speech: Slow, irregular speech with inappropriate pauses
Nystagmus: Gaze-evoked horizontal nystagmus, often vertical

Brainstem Involvement:

Dysphagia (swallowing difficulties)
Dysarthria (speech impairment)
Oculomotor abnormalities

Mermaid diagram (expand to render)

Autonomic Dysfunction

Autonomic failure is a mandatory feature for probable MSA diagnosis:

Cardiovascular Autonomy

Orthostatic Hypotension:

Sustained drop ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing
Occurs in >70% of patients at diagnosis
Often accompanied by supine hypertension

Heart Rate Abnormalities:

Reduced heart rate variability
Impaired baroreflex sensitivity
Cardiac sympathetic denervation (MIBG scintigraphy shows absence of uptake)

Urinary Dysfunction

Early Features:

Urinary urgency and frequency
Nocturia (multiple nighttime awakenings)

Established Disease:

Urinary incontinence (often urge-type)
Incomplete bladder emptying
Recurrent urinary tract infections

Other Autonomic Features

Erectile dysfunction: Often precedes motor symptoms in men
Gastrointestinal dysmotility: Early satiety, nausea, constipation
Anhidrosis: Loss of sweating, particularly on face and trunk

Sleep Disorders

REM Sleep Behavior Disorder (RBD)

Present in up to 80% of MSA patients
Often precedes motor symptoms by years
Characterized by loss of REM atonia, leading to dream enactment
Polysomnography shows elevated REM sleep without atonia

Sleep-Disordered Breathing

Obstructive sleep apnea: Present in ~50%
Central sleep apnea: Particularly in MSA-C variant
Nocturnal stridor: Rare but serious, requires monitoring

Cognitive and Psychiatric Features

Cognitive Profile

Executive dysfunction: Impaired planning, set-shifting, working memory
Processing speed: Significant slowing of information processing
Memory: Relative preservation compared to cortical dementias
Visuospatial: Mild impairment in later stages
Dementia: Present in 10-20%, typically subcortical type

Psychiatric Comorbidities

Depression: Up to 40% prevalence
Anxiety: Common, often co-occurring with depression
Apathy: Present in 20-30%
Psychosis: Less common than in Lewy body dementia

Diagnostic Criteria

Second Consensus Criteria (2008)

Probable MSA:

Sporadic, adult-onset disease
Autonomic failure (orthostatic hypotension + urinary dysfunction)
Plus parkinsonism (bradykinesia + rigidity) OR cerebellar syndrome (gait ataxia + limb ataxia)
Poor response to levodopa

Possible MSA:

Autonomic failure + one of: parkinsonism or cerebellar syndrome
OR parkinsonism/cerebellar syndrome + one of: MRI abnormalities or laboratory findings

Mermaid diagram (expand to render)

Supportive Features

Imaging Findings:

MRI: Putaminal atrophy, pontine atrophy, middle cerebellar peduncle hyperintensity
PET/SPECT: Reduced dopamine transporter binding, regional hypometabolism

Laboratory Findings:

Urinary dysfunction (detrusor overactivity)
Cold extremities with dependent edema

Differential Diagnosis

| Feature | MSA | PSP | CBD | PD |
|---------|-----|-----|-----|-----|
| Autonomic failure | Early, prominent | Late, mild | Late, mild | Late, mild |
| Levodopa response | Poor | Poor | Poor | Good |
| Symmetry | Symmetric | Symmetric | Asymmetric | Asymmetric |
| Disease progression | Rapid | Moderate | Moderate | Slow |
| Eye movements | Rare | Vertical supranuclear gaze palsy | Variable | Normal |

Disease Progression

Early Stage (0-3 years)

Insidious onset of motor symptoms
Early autonomic dysfunction
Often misdiagnosed as PD
Functional independence maintained

Mid Stage (3-6 years)

Progressive motor disability
Frequent falls
Need for assistive devices
Autonomic symptoms become severe

Late Stage (>6 years)

Wheelchair dependence
Severe dysphagia
Nursing home placement common
Median survival: 6-9 years from onset

Clinical Management

Symptomatic Treatment

Parkinsonism: Trial of levodopa, modest benefit in ~30%
Orthostatic hypotension: Midodrine, fludrocortisone, compression stockings
Urinary dysfunction: Oxybutynin, tamsulosin
Depression: SSRIs (cautious due to orthostatic hypotension)

Supportive Care

Physical therapy for gait and balance
Speech therapy for dysarthria and dysphagia
Occupational therapy for activities of daily living
Regular monitoring for sleep-disordered breathing

Conclusion

MSA presents with a distinctive combination of autonomic failure, parkinsonism, and/or cerebellar dysfunction that distinguishes it from other movement disorders. Early recognition of autonomic symptoms and understanding of the clinical variants is critical for accurate diagnosis and appropriate management. The rapid progression and poor treatment response underscore the need for disease-modifying therapies.

References

Unknown (n.d.)

[Gilman et al., Second consensus statement on the diagnosis of MSA (2008)](https://pubmed.ncbi.nlm.nih.gov/18617760/)

[Kaufmann et al., Natural history of autonomic dysfunction in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35820789/)

[Wenning et al., Multiple system atrophy: features and prognosis (2013)](https://doi.org/10.1016/S1474-4422(13)70059-1)

[Stamelou et al., Clinical features of MSA (2012)](https://doi.org/10.1007/s11910-012-0280-7)

[Cohen et al., MRI in multiple system atrophy (2022)](https://doi.org/10.1038/s41582-022-00656-4)

[Fede et al., Autonomic dysfunction in atypical parkinsonism (2020)](https://doi.org/10.1007/s10286-020-00673-4)

📖 View canonical wiki page →